NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)
Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.
You may also be interested in...
Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.
Pfizer warns that price cuts are unsustainable as UK HTA NICE gives provisional backing to Xalkori and Novartis' Afinitor. The drug makers had offered additional, undisclosed price cuts for their cancer therapies.
Pfizer is now poised to tout its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) as a standard of care in both the first and second-line setting for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC), following positive results in the Phase III PROFILE 1014 study.